Evidence map›Paper›PMID 40586389›Full record

ArticleAging and disease2025

Unveiling the Relation between Cellular Aging, Epigenetics and Cancer.

Pawel Kordowitzki, Arkadiusz Grzeczka

Abstract readEditorial
In one paragraph

Article in Aging and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Pawel KordowitzkiDepartment of Basic and Preclinical Sciences, Nicolaus Copernicus University, Toruń, Poland.
Arkadiusz GrzeczkaDepartment of Basic and Preclinical Sciences, Nicolaus Copernicus University, Toruń, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This Editorial article intends to unravel the relationships among cellular aging, epigenetic changes, and tumorigenesis, thereby offering perspectives that could improve therapeutic approaches in cancer management and promote future research on these topics. Furthermore, selected fundamental principles concerning cellular aging will be presented to elucidate how this process contributes to the comprehension of tumorigenesis. As humans age, there is a progressive decline in physiological functions, which significantly increases the risk of cancer. Epigenetic alterations-heritable yet reversible modifications of the genome without changes in DNA sequence-play a pivotal role in both aging and tumorigenesis. Age-associated epigenetic drift, involving widespread DNA methylation changes, histone modification shifts, and chromatin remodelling, disrupts normal gene regulatory networks, leading to genomic instability and impaired cellular homeostasis. Additionally, the accumulation of senescent cells, driven by epigenetic dysregulation, fosters a pro-inflammatory environment that can promote tumorigenesis. Moreover, the epigenetic landscape of aged tissues resembles that of cancerous tissues, suggesting that aging establishes a permissive environment for malignant transformation. Understanding the interplay between aging, epigenetic regulation, and cancer is critical for the development of preventive strategies and novel therapeutics. Epigenetic reprogramming technologies, aiming to restore youthful epigenetic states, hold promise for delaying aging and reducing cancer incidence. However, challenges remain in selectively targeting pathogenic epigenetic changes without disrupting essential cellular functions.

Indexed as

AgingCellular SenescenceEpigenesis, GeneticNeoplasmsAnimalsCarcinogenesisCell Transformation, NeoplasticDNA MethylationHumans

Identifiers

PMID40586389
PMCPMC13256693

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.